A 36-year-old woman attends with her cervical screening result showing hrHPV positive but cytology negative (hrHPV+/cytology-). This is her first cervical screening test since age 25 when her result was normal. She is asymptomatic and has no history of abnormal cervical cytology. She is in a stable relationship and uses the combined oral contraceptive pill. What is the most appropriate management according to current NHS guidelines?
Q122
A 54-year-old woman attends for smoking cessation support. She smokes 18 cigarettes daily and has a 35 pack-year history. She is motivated to quit and requests pharmacological support. She has previously tried nicotine replacement therapy patches without success. She has a history of well-controlled depression managed with citalopram and has no other medical conditions. What would be the most appropriate pharmacological option to offer?
Q123
A 59-year-old man attends for cardiovascular risk assessment as part of the NHS Health Check programme. He has no previous medical history and takes no medications. His father had a myocardial infarction at age 68. Examination reveals BMI 28 kg/m², BP 142/88 mmHg, and xanthelasma around both eyes. Blood tests show total cholesterol 8.2 mmol/L, HDL 1.0 mmol/L, non-HDL 7.2 mmol/L, and fasting glucose 5.4 mmol/L. His QRISK3 score is calculated at 18%. Which diagnosis should be considered and investigated further before initiating standard statin therapy?
Q124
A 50-year-old woman of Ashkenazi Jewish heritage attends requesting genetic testing for hereditary breast cancer. Her sister was diagnosed with breast cancer at age 41 and subsequently found to carry a BRCA1 mutation. The patient is anxious about her own risk. She has no personal history of cancer and clinical examination is normal. What is the most appropriate next step in her management?
Q125
A 44-year-old woman with a BMI of 36 kg/m² attends for weight management review. Over the past 3 months, she has attempted dietary modification and increased physical activity but has only lost 1 kg. She has no contraindications to pharmacological intervention. Her HbA1c is 41 mmol/mol. She requests information about medication to help with weight loss. Which medication would be most appropriate to consider as first-line pharmacological treatment?
Q126
A 61-year-old woman attends for discussion of her NHS bowel cancer screening result. Her faecal immunochemical test (FIT) shows a result of 85 micrograms haemoglobin per gram of faeces. She has no gastrointestinal symptoms and examination is unremarkable. She has well-controlled hypertension and takes ramipril. What is the threshold result that requires referral for colonoscopy in the NHS Bowel Cancer Screening Programme?
Q127
A 26-year-old woman attends for cervical screening. She mentions that she received the HPV vaccination at school when she was 14 years old and asks if she still needs cervical screening. She has been sexually active since age 19 and is currently in a monogamous relationship. She has no gynaecological symptoms. What is the most appropriate advice?
Q128
A 66-year-old man attends following his NHS abdominal aortic aneurysm (AAA) screening ultrasound. The scan reveals an infrarenal AAA measuring 4.8 cm in maximum anteroposterior diameter. He is asymptomatic and his blood pressure is 138/82 mmHg. He stopped smoking 3 years ago and takes atorvastatin for hyperlipidaemia. What is the most appropriate management?
Q129
A 31-year-old woman who is 16 weeks pregnant attends for her anomaly scan appointment. The sonographer identifies that she has not had the combined screening test for Down syndrome and other chromosomal abnormalities (she missed her 12-week appointment). She has no significant medical or family history. What is the most appropriate screening test to offer at this gestation?
Q130
A 68-year-old woman attends for diabetic eye screening. She has had type 2 diabetes for 9 years, current HbA1c 58 mmol/mol. The screening report indicates R1 (background diabetic retinopathy) with microaneurysms in both eyes but no maculopathy. She is asymptomatic with no visual symptoms. What is the appropriate follow-up interval for retinopathy screening?
Screening & Prevention UK Medical PG Practice Questions and MCQs
Question 121: A 36-year-old woman attends with her cervical screening result showing hrHPV positive but cytology negative (hrHPV+/cytology-). This is her first cervical screening test since age 25 when her result was normal. She is asymptomatic and has no history of abnormal cervical cytology. She is in a stable relationship and uses the combined oral contraceptive pill. What is the most appropriate management according to current NHS guidelines?
A. Repeat hrHPV test in 12 months (Correct Answer)
B. Repeat hrHPV test in 24 months
C. Refer for urgent colposcopy within 2 weeks
D. Refer for routine colposcopy
E. Return to routine recall in 3 years
Explanation: ***Repeat hrHPV test in 12 months***
- For individuals who test positive for **high-risk HPV (hrHPV)** but have **negative cytology**, the current NHS guideline is to repeat the test in **12 months** to allow time for the infection to clear spontaneously.
- This is the first step in the **non-referral pathway**, as many HPV infections are transient, especially in women under the age of 50.
*Repeat hrHPV test in 24 months*
- A **24-month** interval is not the standard immediate follow-up for a first-time **hrHPV+/cytology-** result in this age group.
- This timeframe is typically associated with second-year follow-ups of persistent HPV under specific circumstances or older screening intervals.
*Refer for urgent colposcopy within 2 weeks*
- **Urgent 2-week colposcopy** is reserved for cases where screening suggests **invasive cancer** or a clinical suspicion of malignancy based on physical examination.
- There is no clinical indication for urgency here, as the **cytology is negative** and the patient is asymptomatic.
*Refer for routine colposcopy*
- Routine **colposcopy** is indicated if the **hrHPV** test is positive and **cytology is abnormal** (dyskaryosis), or if **hrHPV** persists for 12 or 24 months even with negative cytology.
- Referring immediately after a single negative cytology result would lead to unnecessary invasive procedures for infections that likely clear naturally.
*Return to routine recall in 3 years*
- **Routine recall** is only appropriate if the primary **hrHPV test is negative**, as a negative HPV test indicates a very low risk of developing cervical cancer before the next screen.
- Returning to routine screening while **hrHPV positive** would be unsafe, as it ignores a potentially persistent infection that requires monitoring.
Question 122: A 54-year-old woman attends for smoking cessation support. She smokes 18 cigarettes daily and has a 35 pack-year history. She is motivated to quit and requests pharmacological support. She has previously tried nicotine replacement therapy patches without success. She has a history of well-controlled depression managed with citalopram and has no other medical conditions. What would be the most appropriate pharmacological option to offer?
A. Varenicline
B. Bupropion
C. Nicotine replacement therapy (NRT) combination with patches and short-acting NRT (Correct Answer)
D. Increase citalopram dose and advise behavioural support only
E. Nortriptyline
Explanation: ***Nicotine replacement therapy (NRT) combination with patches and short-acting NRT***
- Given previous failure with **NRT patches alone**, combining a **long-acting NRT** (patch) with a **short-acting NRT** (e.g., gum, lozenge, spray) is a highly effective next step, as per **NICE guidelines**.
- This approach addresses both constant cravings and acute urges, often providing efficacy comparable to varenicline but with a **superior safety profile**, especially important for a patient with a history of well-controlled depression.
*Varenicline*
- While **varenicline** (a **partial nicotine receptor agonist**) is very effective, it can have **neuropsychiatric side effects** and its use might require closer monitoring in patients with a history of depression, even if well-controlled.
- Current guidelines often suggest optimizing NRT first, especially when a patient has already shown familiarity with NRT, before moving to agents like varenicline.
*Bupropion*
- **Bupropion** is contraindicated or should be used with extreme caution in patients taking **SSRIs like citalopram** due to a significantly increased risk of **seizures** and potential drug interactions affecting antidepressant levels.
- Its mechanism as a **norepinephrine-dopamine reuptake inhibitor** differs from direct nicotine replacement, and its side effect profile makes it less suitable given the patient's current medication.
*Increase citalopram dose and advise behavioural support only*
- **Citalopram** is an antidepressant and has **no direct role** in aiding smoking cessation; increasing its dose is not indicated for this purpose and would not address the nicotine dependence.
- While **behavioural support** is crucial, the patient specifically requested **pharmacological support**, and neglecting this by only advising behavioural support would be insufficient and inappropriate.
*Nortriptyline*
- **Nortriptyline**, a **tricyclic antidepressant**, is considered a **second-line** or off-label option for smoking cessation, typically reserved for when first-line options like NRT or varenicline are contraindicated or have failed.
- It carries a higher risk of **anticholinergic side effects** and cardiotoxicity compared to NRT, making it less appropriate as an initial choice for this patient.
Question 123: A 59-year-old man attends for cardiovascular risk assessment as part of the NHS Health Check programme. He has no previous medical history and takes no medications. His father had a myocardial infarction at age 68. Examination reveals BMI 28 kg/m², BP 142/88 mmHg, and xanthelasma around both eyes. Blood tests show total cholesterol 8.2 mmol/L, HDL 1.0 mmol/L, non-HDL 7.2 mmol/L, and fasting glucose 5.4 mmol/L. His QRISK3 score is calculated at 18%. Which diagnosis should be considered and investigated further before initiating standard statin therapy?
A. Hypothyroidism
B. Familial hypercholesterolaemia (Correct Answer)
C. Type 2 diabetes mellitus
D. Nephrotic syndrome
E. Cholestasis
Explanation: ***Familial hypercholesterolaemia***- A total cholesterol **>7.5 mmol/L** or non-HDL cholesterol **>5.9 mmol/L** in an adult mandates clinical suspicion for **Familial hypercholesterolaemia (FH)** according to NICE guidelines.- The presence of **xanthelasma** and a high QRISK score in a patient with severely elevated lipids requires formal assessment using **Simon Broome** or **Dutch Lipid Clinic** criteria before starting standard therapy.*Hypothyroidism*- While **hypothyroidism** is a secondary cause of hyperlipidaemia, it is typically excluded with a **TSH test** but does not explain the specific threshold-based suspicion for FH in this context.- It generally causes a mild to moderate elevation in cholesterol rather than the severe primary elevation seen in this patient.*Type 2 diabetes mellitus*- This patient's **fasting glucose of 5.4 mmol/L** is within the normal range, effectively ruling out a diagnosis of **Type 2 diabetes**.- Diabetes is more commonly associated with **hypertriglyceridemia** and low HDL rather than isolated severe cholesterol elevation.*Nephrotic syndrome*- **Nephrotic syndrome** can cause secondary hyperlipidaemia due to increased hepatic lipoprotein synthesis, but there is no mention of **oedema** or proteinuria here.- It remains a differential for secondary lipid elevation but is less likely than a primary genetic lipid disorder given the clinical presentation.*Cholestasis*- **Cholestasis** can lead to elevated cholesterol levels due to decreased biliary excretion, but it would typically present with **jaundice** or pruritus.- There are no symptoms or signs of **liver disease** or biliary obstruction provided in the clinical history to support this diagnosis.
Question 124: A 50-year-old woman of Ashkenazi Jewish heritage attends requesting genetic testing for hereditary breast cancer. Her sister was diagnosed with breast cancer at age 41 and subsequently found to carry a BRCA1 mutation. The patient is anxious about her own risk. She has no personal history of cancer and clinical examination is normal. What is the most appropriate next step in her management?
A. Arrange BRCA1 genetic testing directly through the GP
B. Reassure and arrange annual mammography through the NHS Breast Screening Programme
C. Refer to clinical genetics service for assessment and cascade testing (Correct Answer)
D. Prescribe tamoxifen for chemoprevention
E. Refer to breast surgery for discussion of prophylactic mastectomy
Explanation: ***Refer to clinical genetics service for assessment and cascade testing***
- The patient has a **first-degree relative** with a confirmed **BRCA1 mutation** and is of **Ashkenazi Jewish heritage**, indicating a high likelihood of a pathogenic variant. This warrants a formal **genetic risk assessment** and **pre-test counseling**.
- A referral to a **specialist clinical genetics service** ensures appropriate interpretation of results, discussion of implications for family members (**cascade testing**), and tailored surveillance/risk reduction strategies.
*Arrange BRCA1 genetic testing directly through the GP*
- **Germline genetic testing** for hereditary cancer syndromes is complex and requires specialized **pre-test and post-test counseling** that GPs are not typically equipped to provide.
- Without proper **genetic counseling**, misinterpretation of results or inadequate support can lead to significant psychological distress and inappropriate medical decisions.
*Reassure and arrange annual mammography through the NHS Breast Screening Programme*
- Given the strong family history and known **BRCA1 mutation** in a first-degree relative, the patient is at **high risk** and requires more intensive surveillance than routine screening.
- Standard **NHS Breast Screening** is insufficient; high-risk individuals require **enhanced surveillance protocols**, potentially including annual MRI, which are managed by specialized genetics services or high-risk clinics.
*Prescribe tamoxifen for chemoprevention*
- **Chemoprevention** with agents like **tamoxifen** is only considered after a formal **genetic risk assessment** confirms a high lifetime risk of breast cancer and is discussed with the patient after they understand the benefits and risks.
- Prescribing **tamoxifen** without confirming the patient's genetic status and completing a comprehensive risk-benefit discussion is premature and not evidence-based.
*Refer to breast surgery for discussion of prophylactic mastectomy*
- **Prophylactic mastectomy** is a major surgical intervention reserved for individuals with **confirmed high genetic risk** (e.g., BRCA1/2 mutation carriers) and after extensive counseling by a multidisciplinary team.
- Referring for surgery before the patient's **genetic status** is confirmed and a thorough risk assessment by a **genetics service** is conducted is premature and inappropriate.
Question 125: A 44-year-old woman with a BMI of 36 kg/m² attends for weight management review. Over the past 3 months, she has attempted dietary modification and increased physical activity but has only lost 1 kg. She has no contraindications to pharmacological intervention. Her HbA1c is 41 mmol/mol. She requests information about medication to help with weight loss. Which medication would be most appropriate to consider as first-line pharmacological treatment?
A. Metformin 500 mg twice daily
B. Orlistat 120 mg three times daily with meals (Correct Answer)
C. Liraglutide 3.0 mg subcutaneous injection daily
D. Semaglutide 2.4 mg subcutaneous injection weekly
E. Bupropion-naltrexone combination
Explanation: ***Orlistat 120 mg three times daily with meals***
- The patient's **BMI of 36 kg/m²** and failure of lifestyle modifications for 3 months meet the criteria for **first-line pharmacological treatment** for weight loss, as per guidelines (e.g., NICE).
- **Orlistat** works as a **gastrointestinal lipase inhibitor**, reducing the absorption of dietary fat, making it an appropriate initial choice when no contraindications exist and HbA1c is normal.
*Metformin 500 mg twice daily*
- **Metformin** is primarily indicated for **Type 2 Diabetes Mellitus** or **pre-diabetes**; the patient's HbA1c of 41 mmol/mol indicates she is **non-diabetic** and does not require metformin for glycemic control.
- Although it can lead to some weight loss, it is **not licensed** as a first-line agent for weight management in individuals without diabetes.
*Liraglutide 3.0 mg subcutaneous injection daily*
- While effective for weight loss, **Liraglutide** (at the 3.0 mg dose) is generally reserved for use within **specialist weight management services** (e.g., Tier 3/4) and is not considered a first-line primary care option.
- It is typically considered for patients with higher BMI thresholds or specific comorbidities, often after initial interventions like orlistat or lifestyle changes have been explored.
*Semaglutide 2.4 mg subcutaneous injection weekly*
- **Semaglutide** (at 2.4 mg for weight management) is a potent GLP-1 receptor agonist; however, its use is usually restricted to patients with a **BMI of 35 kg/m² or more with at least one weight-related comorbidity**, or a BMI of 30 kg/m² with specific criteria, and initiated by **specialist services**.
- It is not typically the first-line pharmacological treatment in primary care for a patient who does not meet these more stringent criteria or require specialist initiation.
*Bupropion-naltrexone combination*
- The **bupropion-naltrexone combination** is not currently recommended as a first-line agent for routine weight management by key national guidelines (e.g., NICE) in the UK.
- It carries a different side effect profile, including potential **neuropsychiatric adverse effects**, making it less favorable than established first-line treatments like orlistat for this patient.
Question 126: A 61-year-old woman attends for discussion of her NHS bowel cancer screening result. Her faecal immunochemical test (FIT) shows a result of 85 micrograms haemoglobin per gram of faeces. She has no gastrointestinal symptoms and examination is unremarkable. She has well-controlled hypertension and takes ramipril. What is the threshold result that requires referral for colonoscopy in the NHS Bowel Cancer Screening Programme?
A. ≥10 micrograms Hb per gram faeces (Correct Answer)
B. ≥40 micrograms Hb per gram faeces
C. ≥150 micrograms Hb per gram faeces
D. ≥100 micrograms Hb per gram faeces
E. ≥200 micrograms Hb per gram faeces
Explanation: ***≥10 micrograms Hb per gram faeces***
- In the **NHS Bowel Cancer Screening Programme**, the specific threshold for a positive **Faecal Immunochemical Test (FIT)** result requiring urgent colonoscopy referral is **≥10 µg Hb/g**.
- This threshold is sensitive enough to detect **colorectal cancer** and **advanced adenomas** in asymptomatic individuals within the screening age range.
*≥40 micrograms Hb per gram faeces*
- This value is higher than the official **NHS screening cutoff**, potentially missing significant pathology if used as a referral gatekeeper.
- Although some clinical pathways for **symptomatic** patients use different variations, the national screening standard remains **10 µg Hb/g**.
*≥150 micrograms Hb per gram faeces*
- This level is significantly higher than the standard threshold and would result in many **false negatives** for early-stage malignancy.
- A result of 150 µg Hb/g indicates a high likelihood of colorectal pathology, but the screening programme triggers action at a much lower level to ensure **early detection**.
*≥100 micrograms Hb per gram faeces*
- Some **FIT** assays previously used higher cut-offs in different jurisdictions, but the **Public Health England** guidelines for the screening programme utilize the **10 µg Hb/g** limit.
- Using a **100 µg Hb/g** threshold would overlook the majority of patients with high-risk **polyps**.
*≥200 micrograms Hb per gram faeces*
- This represents a very high concentration of **occult blood** and is not used as a screening threshold as it lacks the necessary **sensitivity** for a population-wide program.
- The goal of the **FIT** in screening is to catch lesions before they become symptomatic, which necessitates the lower **10 µg Hb/g** threshold.
Question 127: A 26-year-old woman attends for cervical screening. She mentions that she received the HPV vaccination at school when she was 14 years old and asks if she still needs cervical screening. She has been sexually active since age 19 and is currently in a monogamous relationship. She has no gynaecological symptoms. What is the most appropriate advice?
A. She does not need cervical screening as she was vaccinated
B. She should commence cervical screening now
C. She should wait until age 30 to commence cervical screening
D. She only needs screening if she develops symptoms
E. She should commence cervical screening at age 25 (Correct Answer)
Explanation: ***She should commence cervical screening at age 25***
- In the UK, the **NHS Cervical Screening Programme** invites all individuals with a cervix to begin screening at **age 25**, regardless of their **HPV vaccination status**.
- While the vaccine protects against high-risk types like **HPV 16 and 18**, it does not cover all **oncogenic HPV types**, making regular screening essential for early detection.
*She does not need cervical screening as she was vaccinated*
- **HPV vaccination** significantly reduces the risk of cervical cancer but does not eliminate it entirely, as other **high-risk HPV strains** are not covered by older vaccines.
- Screening is still required to identify **pre-cancerous changes** (CIN) caused by non-vaccine HPV types.
*She should commence cervical screening now*
- At age 26, she is already within the recommended age bracket, but the standard protocol specifies that the first invitation is sent at **age 25**.
- Commencing screening earlier than age 25 is not recommended as **transient HPV infections** and minor cell changes are common and usually resolve without clinical significance.
*She should wait until age 30 to commence cervical screening*
- Waiting until age 30 would miss the critical window for identifying early **dysplastic changes** often found in the 25-29 age group.
- Current guidelines mandate screening every **three years** for those aged **25–49** to ensure adequate monitoring.
*She only needs screening if she develops symptoms*
- Cervical screening is a **preventative tool** designed to detect asymptomatic **precancerous lesions** before they progress to invasive cancer.
- Once symptoms like **post-coital bleeding** occur, the focus shifts from screening to **diagnostic investigation** (colposcopy or biopsy).
Question 128: A 66-year-old man attends following his NHS abdominal aortic aneurysm (AAA) screening ultrasound. The scan reveals an infrarenal AAA measuring 4.8 cm in maximum anteroposterior diameter. He is asymptomatic and his blood pressure is 138/82 mmHg. He stopped smoking 3 years ago and takes atorvastatin for hyperlipidaemia. What is the most appropriate management?
A. Discharge with no follow-up required
B. Refer for urgent vascular surgery review within 2 weeks
C. Arrange repeat ultrasound surveillance in 3 months (Correct Answer)
D. Arrange repeat ultrasound surveillance in 12 months
E. Arrange CT angiography and routine vascular surgery referral
Explanation: ***Arrange repeat ultrasound surveillance in 3 months***
- This patient has a **medium-sized abdominal aortic aneurysm (AAA)**, defined as measuring between **4.5 cm and 5.4 cm** in maximum diameter.
- According to **NHS AAA screening guidelines**, medium aneurysms require **3-monthly ultrasound surveillance** to monitor for growth and assess the need for intervention.
*Discharge with no follow-up required*
- Any AAA measuring **3.0 cm or greater** requires ongoing monitoring to assess for growth and reduce the risk of rupture.
- A **4.8 cm infrarenal AAA** carries a significant risk of progression, making discharge without follow-up clinically inappropriate and unsafe.
*Refer for urgent vascular surgery review within 2 weeks*
- Urgent vascular surgery referral is indicated for **large AAAs (≥5.5 cm)**, symptomatic aneurysms (e.g., pain), or those with rapid expansion (e.g., **>1 cm in a year**).
- This patient's aneurysm is **4.8 cm** and **asymptomatic**, so it does not meet the criteria for urgent surgical review at this stage.
*Arrange repeat ultrasound surveillance in 12 months*
- **Annual (12-month) surveillance** is the standard protocol for **small AAAs**, which are defined as measuring between **3.0 cm and 4.4 cm** in diameter.
- For a **4.8 cm aneurysm**, a one-year interval is too long and increases the risk of the aneurysm reaching a critical size without timely detection.
*Arrange CT angiography and routine vascular surgery referral*
- **CT angiography** is typically used for pre-operative planning or when the aneurysm reaches the **5.5 cm threshold** for surgical consideration.
- Routine referral and advanced imaging like CT angiography are not indicated for an **asymptomatic medium AAA** that is currently managed under a surveillance program.
Question 129: A 31-year-old woman who is 16 weeks pregnant attends for her anomaly scan appointment. The sonographer identifies that she has not had the combined screening test for Down syndrome and other chromosomal abnormalities (she missed her 12-week appointment). She has no significant medical or family history. What is the most appropriate screening test to offer at this gestation?
A. Quadruple test (AFP, hCG, uE3, inhibin A) (Correct Answer)
B. Non-invasive prenatal testing (NIPT) with cell-free fetal DNA
C. Amniocentesis for definitive karyotyping
D. Combined test with nuchal translucency measurement and serum markers
E. Arrange early anatomy scan for soft markers of chromosomal abnormality
Explanation: ***Quadruple test (AFP, hCG, uE3, inhibin A)***- The **quadruple test** is the screening test of choice for **Down syndrome** and other chromosomal abnormalities in the second trimester, specifically between **14+2 and 20+0 weeks** of gestation.- It measures four biochemical markers (**AFP, hCG, uE3, inhibin A**) and is used when the window for the combined test has passed, as in this case at 16 weeks.*Non-invasive prenatal testing (NIPT) with cell-free fetal DNA*- **NIPT** is a highly sensitive screening test but is typically offered as a **contingent test** for women who receive a high-risk result from initial screening (e.g., combined or quadruple test).- While it can be performed after 10 weeks, it is not currently the standard **first-line screening alternative** offered to the general population in the second trimester after a missed initial screening.*Amniocentesis for definitive karyotyping*- **Amniocentesis** is an **invasive diagnostic procedure**, not a screening test, and carries a small but significant **risk of miscarriage** (approx. 0.5-1%).- It is generally reserved for **confirming chromosomal abnormalities** after an increased risk is identified by screening tests or ultrasound findings, not as an initial screening offer.*Combined test with nuchal translucency measurement and serum markers*- The **combined test** is only valid between **11+2 and 14+1 weeks** because nuchal translucency measurement is no longer accurate or clinically useful beyond this gestational window.- At **16 weeks gestation**, this patient has missed the clinical window for this specific screening modality.*Arrange early anatomy scan for soft markers of chromosomal abnormality*- The **anomaly scan** (usually performed at 18-20 weeks) focuses on **structural defects** rather than being a primary screening tool for chromosomal trisomies.- Relying solely on "soft markers" for initial screening has a lower detection rate and higher **false-positive rates** compared to biochemical screening tests like the quadruple test.
Question 130: A 68-year-old woman attends for diabetic eye screening. She has had type 2 diabetes for 9 years, current HbA1c 58 mmol/mol. The screening report indicates R1 (background diabetic retinopathy) with microaneurysms in both eyes but no maculopathy. She is asymptomatic with no visual symptoms. What is the appropriate follow-up interval for retinopathy screening?
A. Routine annual screening (Correct Answer)
B. Repeat screening in 6 months
C. Urgent referral to ophthalmology within 2 weeks
D. Routine referral to ophthalmology
E. Repeat screening in 3 months
Explanation: ***Routine annual screening***- For patients with **R1 (background retinopathy)** and no evidence of maculopathy, the standard management is surveillance via **annual screening**.- This staging involves **microaneurysms** or small hemorrhages only, which carry a low risk of immediate vision loss and do not require clinical intervention.*Repeat screening in 6 months*- A **6-month interval** is usually reserved for stable **pre-proliferative changes** in specific monitoring programs, not for standard R1 background retinopathy.- Increasing frequency is unnecessary for **microaneurysms** alone, as progression to vision-threatening disease typically occurs over a longer duration.*Urgent referral to ophthalmology within 2 weeks*- Urgent 2-week referrals are strictly indicated for **R3 (proliferative retinopathy)**, characterized by **neovascularization** or vitreous hemorrhage.- This patient is **asymptomatic** and lacks the high-risk features necessary for emergency specialist evaluation.*Routine referral to ophthalmology*- Routine ophthalmology referral is indicated for **M1 (maculopathy)** or **R2 (pre-proliferative)** changes, neither of which are present in this case.- Patients with **R1 level retinopathy** are managed by the diabetic eye screening service rather than hospital clinic specialists.*Repeat screening in 3 months*- A **3-month interval** is not a standard screening frequency and would typically be part of a specialist's intensive monitoring for rapidly progressing disease.- **Background retinopathy** does not warrant such close follow-up since it is the earliest stage of clinical diabetic eye disease.
